WASHINGTON, D.C.—As of November 2024, there are 16 biologic disease-modifying anti-rheumatic drugs (bDMARDs) that are FDA approved for the treatment of psoriatic arthritis (PsA). Incredible news, right? But as my fellowship program director used to say, “There’s no free lunch.” This buffet of options is excellent for our patients, but poses challenges to the practicing…
Background/Purpose Psoriasis and psoriatic arthritis (PsA) are closely linked inflammatory conditions that can affect both children and adults. In children, these diseases are associated with traditional cardiovascular disease risk factors and subclinical atherosclerosis. In older adults, systemic inflammation from psoriasis and PsA accelerates atherosclerosis, and these conditions are independent risk factors for severe cardiovascular disease…
There’s still time to contribute and attend RheumPAC’s event at ACR Convergence 2024. If you haven’t yet made your 2024 donation, this is the best time to do so—thanks to generous champions, every contribution will be amplified.
Axial spondyloarthritis (axSpA) is a complex, immune-mediated inflammatory disorder characterized by inflammatory back pain and axial arthritis. Typical of other diseases in the spondyloarthritis family, the clinical phenotypes can be diverse, and an array of comorbidities often accompanies the spinal disease. “In this Meet the Professor Session at ACR Convergence 2024,” says Christopher Ritchlin, MD,…
Sessions on the use of AI to aid documentation and on hiring advanced practice providers could help your rheumatology practice save time and money.
In sessions in the business of rheumatology track, rheumatology practice leaders will share ways to manage payer complexities head-on while also improving patient care.
With more than 350 research abstracts on systemic lupus erythematosus, lupus nephritis and related conditions accepted for presentation at ACR Convergence 2024, we’re happy to announce that Graciela S. Alarcón, MD, MPH, has accepted the monumental task of reviewing the abstracts and identifying those most likely to make a difference to clinical practice or lead…
An ACR Convergence 2024 session will discuss strategies to educate patients about their disease and review the progress toward the concept of remission in gout to better guide physicians.
In a session at ACR Convergence 2024, expert panelists with go into depth concerning molecular mechanisms that contribute to gout pathogenesis.
A new guideline, the 2024 Updated ACR Guideline for the Diagnosis and Treatment of Lupus Nephritis, is being introduced at ACR Convergence 2024 on Monday, Nov. 18. In the session, Lisa Sammaritano, MD, professor of clinical medicine at Weill Cornell Medicine and Hospital for Special Surgery, New York, will discuss the guideline development process and…